Replay is pioneering advancements in genomic medicine through the innovative use of engineered herpes simplex virus type 1 (HSV-1) technology. This approach allows for the delivery of large DNA constructs, significantly exceeding the payload capacity of traditional adeno-associated virus (AAV) vectors. Specifically, Replay's HSV technology can deliver up to 150 kilobases of DNA, which is approximately 30 times the capacity of AAV, enabling the transfer of complex genomic elements and multiple genes. This capability is particularly crucial for addressing polygenic conditions, where multiple genes may need to be targeted simultaneously for effective treatment.

The company's focus on high payload delivery systems positions it to tackle challenges in gene therapy, especially for conditions that require the expression of large genes or intricate regulatory elements. By leveraging HSV-1, Replay aims to facilitate the development of autologous, allogeneic, and induced pluripotent stem cell (iPSC)-derived therapies. This technology not only enhances the potential for multiplexing chimeric antigen receptors (CARs) and T cell receptors (TCRs) but also opens new avenues for treating rare diseases and complex genetic disorders, thereby redefining the landscape of gene therapy.

United States

Replay is a genome writing company, which aims to define the future of genomic medicine through reprogramming biology by writing and reprogramming biology.

Replay

Company Details